| scholarly article | Q13442814 |
| P50 | author | Md Nazir Hossen | Q87830272 |
| Cody J Peer | Q89302968 | ||
| Chandra Kumar Elechalawar | Q89907291 | ||
| William Douglas Figg, Sr. | Q16195062 | ||
| P2093 | author name string | J David Robertson | |
| Resham Bhattacharya | |||
| Priyabrata Mukherjee | |||
| Priya Shankarappa | |||
| P2860 | cites work | Stability and freeze-drying of cyclosporine loaded poly(D,L lactide-glycolide) carriers | Q57108372 |
| Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes | Q59334865 | ||
| Biodistribution of PEG-modified gold nanoparticles following intratracheal instillation and intravenous injection | Q62098835 | ||
| Enhanced hydrogel adhesion by polymer interdiffusion: use of linear poly(ethylene glycol) as an adhesion promoter | Q73339605 | ||
| Freeze-drying of bioproducts: putting principles into practice | Q74755082 | ||
| Eligibility of Metastatic Pancreatic Cancer Patients for First-Line Palliative Intent nab-Paclitaxel Plus Gemcitabine Versus FOLFIRINOX | Q87058753 | ||
| Cancer statistics, 2019 | Q90941571 | ||
| Gold Nanoparticle Transforms Activated Cancer-Associated Fibroblasts to Quiescence | Q92220582 | ||
| Pharmacokinetics and biodistribution of nanoparticles | Q37210459 | ||
| Gemcitabine versus Modified Gemcitabine: a review of several promising chemical modifications | Q38043484 | ||
| The polyethyleneglycol dilemma: advantage and disadvantage of PEGylation of liposomes for systemic genes and nucleic acids delivery to tumors. | Q38111201 | ||
| FOLFIRINOX - a new paradigm in the treatment of pancreatic cancer | Q38247470 | ||
| Molecular evidence for increased antitumor activity of gemcitabine in combination with a cyclin-dependent kinase inhibitor, P276-00 in pancreatic cancers | Q39300788 | ||
| Pancreatic cancer associated fibroblasts display normal allelotypes. | Q40001815 | ||
| Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent | Q40002504 | ||
| Gemcitabine: metabolism, mechanisms of action, and self-potentiation. | Q40371567 | ||
| Tuning pharmacokinetics and biodistribution of a targeted drug delivery system through incorporation of a passive targeting component | Q42730813 | ||
| Effect of PEG molecular weight and PEGylation degree on the physical stability of PEGylated lysozyme. | Q46426670 | ||
| Cleavable PEGylation: a strategy for overcoming the "PEG dilemma" in efficient drug delivery | Q47288830 | ||
| Effect of Surface Chemistry and Associated Protein Corona on the Long-Term Biodegradation of Iron Oxide Nanoparticles In Vivo. | Q48253916 | ||
| Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. | Q51376589 | ||
| Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. | Q53621609 | ||
| Micro- and macrorheology of mucus | Q24643968 | ||
| An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. | Q27336445 | ||
| A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs | Q28285226 | ||
| Designing nanoconjugates to effectively target pancreatic cancer cells in vitro and in vivo | Q28478752 | ||
| Inhibiting the growth of pancreatic adenocarcinoma in vitro and in vivo through targeted treatment with designer gold nanotherapeutics | Q28487715 | ||
| Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial | Q29547565 | ||
| FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer | Q29547638 | ||
| Pancreatic cancer | Q29616288 | ||
| ERBB receptors and cancer: the complexity of targeted inhibitors | Q29619520 | ||
| Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus | Q30478934 | ||
| Overexpression of smoothened activates the sonic hedgehog signaling pathway in pancreatic cancer-associated fibroblasts | Q30493907 | ||
| PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo | Q30493965 | ||
| Biodegradable nanoparticles composed entirely of safe materials that rapidly penetrate human mucus | Q35002405 | ||
| Potential therapeutic application of gold nanoparticles in B-chronic lymphocytic leukemia (BCLL): enhancing apoptosis | Q35808025 | ||
| Desmoplasia in Primary Tumors and Metastatic Lesions of Pancreatic Cancer | Q35920843 | ||
| Unlike pancreatic cancer cells pancreatic cancer associated fibroblasts display minimal gene induction after 5-aza-2'-deoxycytidine | Q36226867 | ||
| Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer | Q36238771 | ||
| Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles | Q36319725 | ||
| Freeze-drying of nanoparticles: formulation, process and storage considerations | Q36659686 | ||
| What is the future of PEGylated therapies? | Q37006106 | ||
| Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier | Q37153146 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P921 | main subject | pancreatic cancer | Q212961 |
| P304 | page(s) | 991-1003 | |
| P577 | publication date | 2020-02-13 | |
| P1433 | published in | International Journal of Nanomedicine | Q6051502 |
| P1476 | title | Targeting Pancreatic Cancer Cells and Stellate Cells Using Designer Nanotherapeutics in vitro | |
| P478 | volume | 15 |
Search more.